Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.52 |
| ▸ | CTSL | P07711 | 11/20 | 0.51 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408243 | 0.78 | CTSS (0.53) | CTSSCTSLCTSKALOX5EPHX2 | |
| SCHEMBL6691416 | 0.78 | CTSS (0.53) | CTSSCTSLCTSKALOX5EPHX2 | |
| SCHEMBL3014808 | 0.78 | CTSS (0.63) | CTSSCTSLCTSKALOX5EPHX2 | |
| SCHEMBL3014805 | 0.78 | CTSS (0.63) | CTSSCTSLCTSKALOX5EPHX2 | |
| SCHEMBL5362588 | 0.77 | CTSS (0.63) | CTSSCTSLCTSK | |
| SCHEMBL14277832 | 0.76 | CTSS (0.58) | CTSSCTSLCTSKNPY5R | |
| SCHEMBL5359602 | 0.76 | CTSS (0.62) | CTSSCTSLCTSKALOX5EPHX2 | |
| SCHEMBL3024690 | 0.76 | CTSS (0.62) | CTSSCTSLCTSKALOX5EPHX2 | |
| SCHEMBL4796381 | 0.75 | CTSS (0.61) | CTSSCTSLCTSK | |
| SCHEMBL4796386 | 0.75 | CTSS (0.61) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307095-B2 | Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide | IRM LLC (BM) | 2007-12-11 | — | — | US | disclosed |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-05-31 | — | — | US | disclosed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | disclosed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049244-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.